Genesystem Balance Sheet Health
Financial Health criteria checks 3/6
Genesystem has a total shareholder equity of ₩28.8B and total debt of ₩3.9B, which brings its debt-to-equity ratio to 13.7%. Its total assets and total liabilities are ₩35.2B and ₩6.5B respectively.
Key information
13.7%
Debt to equity ratio
₩3.94b
Debt
| Interest coverage ratio | n/a |
| Cash | ₩16.73b |
| Equity | ₩28.78b |
| Total liabilities | ₩6.46b |
| Total assets | ₩35.24b |
Recent financial health updates
Recent updates
Financial Position Analysis
Short Term Liabilities: A363250's short term assets (₩21.4B) exceed its short term liabilities (₩2.1B).
Long Term Liabilities: A363250's short term assets (₩21.4B) exceed its long term liabilities (₩4.4B).
Debt to Equity History and Analysis
Debt Level: A363250 has more cash than its total debt.
Reducing Debt: Insufficient data to determine if A363250's debt to equity ratio has reduced over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Insufficient data to determine if A363250 has enough cash runway based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if A363250 has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.